Cargando…
Adhesins as targets for vaccine development.
Blocking the primary stages of infection, namely bacterial attachment to host cell receptors and colonization of the mucosal surface, may be the most effective strategy to prevent bacterial infections. Bacterial attachment usually involves an interaction between a bacterial surface protein called an...
Autores principales: | , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Centers for Disease Control and Prevention
1999
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2640765/ https://www.ncbi.nlm.nih.gov/pubmed/10341176 |
_version_ | 1782164592577740800 |
---|---|
author | Wizemann, T M Adamou, J E Langermann, S |
author_facet | Wizemann, T M Adamou, J E Langermann, S |
author_sort | Wizemann, T M |
collection | PubMed |
description | Blocking the primary stages of infection, namely bacterial attachment to host cell receptors and colonization of the mucosal surface, may be the most effective strategy to prevent bacterial infections. Bacterial attachment usually involves an interaction between a bacterial surface protein called an adhesin and the host cell receptor. Recent preclinical vaccine studies with the FimH adhesin (derived from uropathogenic Escherichia coli) have confirmed that antibodies elicited against an adhesin can impede colonization, block infection, and prevent disease. The studies indicate that prophylactic vaccination with adhesins can block bacterial infections. With recent advances in the identification, characterization, and isolation of other adhesins, similar approaches are being explored to prevent infections, from otitis media and dental caries to pneumonia and sepsis. |
format | Text |
id | pubmed-2640765 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 1999 |
publisher | Centers for Disease Control and Prevention |
record_format | MEDLINE/PubMed |
spelling | pubmed-26407652009-05-20 Adhesins as targets for vaccine development. Wizemann, T M Adamou, J E Langermann, S Emerg Infect Dis Research Article Blocking the primary stages of infection, namely bacterial attachment to host cell receptors and colonization of the mucosal surface, may be the most effective strategy to prevent bacterial infections. Bacterial attachment usually involves an interaction between a bacterial surface protein called an adhesin and the host cell receptor. Recent preclinical vaccine studies with the FimH adhesin (derived from uropathogenic Escherichia coli) have confirmed that antibodies elicited against an adhesin can impede colonization, block infection, and prevent disease. The studies indicate that prophylactic vaccination with adhesins can block bacterial infections. With recent advances in the identification, characterization, and isolation of other adhesins, similar approaches are being explored to prevent infections, from otitis media and dental caries to pneumonia and sepsis. Centers for Disease Control and Prevention 1999 /pmc/articles/PMC2640765/ /pubmed/10341176 Text en https://creativecommons.org/licenses/by/4.0/This is a publication of the U.S. Government. This publication is in the public domain and is therefore without copyright. All text from this work may be reprinted freely. Use of these materials should be properly cited. |
spellingShingle | Research Article Wizemann, T M Adamou, J E Langermann, S Adhesins as targets for vaccine development. |
title | Adhesins as targets for vaccine development. |
title_full | Adhesins as targets for vaccine development. |
title_fullStr | Adhesins as targets for vaccine development. |
title_full_unstemmed | Adhesins as targets for vaccine development. |
title_short | Adhesins as targets for vaccine development. |
title_sort | adhesins as targets for vaccine development. |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2640765/ https://www.ncbi.nlm.nih.gov/pubmed/10341176 |
work_keys_str_mv | AT wizemanntm adhesinsastargetsforvaccinedevelopment AT adamouje adhesinsastargetsforvaccinedevelopment AT langermanns adhesinsastargetsforvaccinedevelopment |